Noticias de ATHE_US

Noticias del mercado

Últimas noticias sobre ATHE_US — 148 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ATHE_US ✕ 148 resultados
27/04/2026 ATHE_US — The Manila Times
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
26/04/2026 ATHE_US — MSN ES ← EN
Alterity Therapeutics Limited - El precio objetivo del recibo de depósito (ATHE) aumentó un 18,07 % hasta 3,98

Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target increased by 18.07% to 3.98

26/04/2026 ATHE_US — MarketScreener
Alterity Therapeutics receives positive FDA feedback on ATH434 phase 3 program
26/04/2026 ATHE_US — MarketScreener
Alterity Therapeutics Secures US FDA Support for ATH434 Phase Three Program
25/04/2026 ATHE_US — MSN ES ← EN
Alterity Therapeutics Limited - El precio objetivo del recibo de depósito (ATHE) aumentó un 18,07 % hasta 3,98

Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target increased by 18.07% to 3.98

24/04/2026 ATHE_US — MSN ES ← EN
Alterity Therapeutics Limited - El precio objetivo del recibo de depósito (ATHE) aumentó un 66,70% a 6,64

Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target increased by 66.70% to 6.64

23/04/2026 ATHE_US — MSN ES ← EN
Alterity Therapeutics Limited - El precio objetivo del recibo de depósito (ATHE) aumentó un 18,07 % hasta 3,98

Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target increased by 18.07% to 3.98

22/04/2026 ATHE_US — sonla.gov.vn
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Profit Margin
22/04/2026 ATHE_US — Xã Thanh Hà
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Profit Margin
22/04/2026 ATHE_US — tayninh.gov.vn
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Profit Margin
22/04/2026 ATHE_US — news.google.com
ATHE (Alterity Therapeutics Limited American Depositary Shares) gains 3.04 percent after Q3 2025 earnings despite posting negative quarterly earnings per share. - Profit Margin
22/04/2026 ATHE_US — Stock Titan
ATH434 Phase 2 MSA data highlight disease signal at Alterity (NASDAQ: ATHE)
22/04/2026 ATHE_US — Yahoo Finance
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
22/04/2026 ATHE_US — Stock Titan
A new analysis points to slower decline in MSA as Alterity eyes Phase 3
22/04/2026 ATHE_US — The Manila Times
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
21/04/2026 ATHE_US — The Globe and Mail
Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding
21/04/2026 ATHE_US — Stock Titan
Ann Cunningham joins Alterity Therapeutics (NASDAQ: ATHE) board with no declared holdings
20/04/2026 ATHE_US — MSN ES ← EN
Alterity Therapeutics Limited - El precio objetivo del recibo de depósito (ATHE) aumentó un 18,07 % hasta 3,98
20/04/2026 ATHE_US — Stock Titan ES ← EN
[6-K] ALTERITY THERAPEUTICS LTD Informe actual (Emisor extranjero) | Presentación ATHE ante la SEC: formulario 6-K

[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K

20/04/2026 ATHE_US — Stock Titan ES ← EN
[6-K] ALTERITY THERAPEUTICS LTD Informe actual (Emisor extranjero) | Presentación ATHE ante la SEC: formulario 6-K

[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K

Página 5 de 8

keyboard_arrow_up